Pfizer reports positive results for Talzenna/Xtandi combo
Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of ...
FiercePharma5d
Pfizer outlines Talzenna's survival benefit in bid for broad prostate cancer approval
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...
Pharmabiz4d
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
Morningstar6d
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
TALZENNA in combination with XTANDI was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with HRR gene-mutated mCRPC in June 2023. The combination was ...
The American Journal of Managed Care4d
TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
BioPharma Dive5d
RFK Jr. confirmed by Senate as health secretary
All but one Senate Republican voted for Kennedy, a controversial vaccine critic whose embrace of the “Make America Healthy ...